Methenamine hippurate clinical pharmacology

Revision as of 14:56, 9 January 2014 by Abdurahman Khalil (talk | contribs) (Created page with "__NOTOC__ {{Methenamine hippurate}} {{CMG}}; {{AE}} {{AK}} Within 1/2 hour after ingestion of a single 1-gram dose of methenamine hippurate USP, antibacterial activity is dem...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Methenamine hippurate
HIPREX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Within 1/2 hour after ingestion of a single 1-gram dose of methenamine hippurate USP, antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity when methenamine hippurate USP is administered at the recommended dosage schedule of 1 gram twice daily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1-gram dose. Similarly, the hippurate moiety is rapidly absorbed and excreted, and it reaches the urine by both tubular secretion and glomerular filtration. This action may be important in older patients or in those with some degree of renal impairment.



References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17681s014lbl.pdf